Compare · ADPT vs ARGX
ADPT vs ARGX
Side-by-side comparison of Adaptive Biotechnologies Corporation (ADPT) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADPT and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 15.1x ADPT ($4.19B).
- ARGX has been more active in the news (11 items in the past 4 weeks vs 8 for ADPT).
- ARGX has more recent analyst coverage (25 ratings vs 16 for ADPT).
- Company
- Adaptive Biotechnologies Corporation
- argenx SE
- Price
- -
- -
- Market cap
- $4.19B
- $63.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2017
- News (4w)
- 8
- 11
- Recent ratings
- 16
- 25
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ADPT
- Director Hershberg Robert exercised 15,000 shares at a strike of $6.32 and sold $748,208 worth of shares (30,664 units at $24.40), decreasing direct ownership by 25% to 46,683 units (SEC Form 4)
- CEO and Chairman Robins Chad M exercised 600,000 shares at a strike of $6.55 and sold $14,882,166 worth of shares (600,000 units at $24.80) (SEC Form 4)
- Director Neupert Peter M sold $3,135,850 worth of shares (124,690 units at $25.15) and exercised 15,000 shares at a strike of $6.32, decreasing direct ownership by 46% to 130,625 units (SEC Form 4)
- SEC Form 144 filed by Adaptive Biotechnologies Corporation
- SEC Form 144 filed by Adaptive Biotechnologies Corporation
- Chief Commercial Officer, MRD Bobulsky Susan sold $75,000 worth of shares (3,000 units at $25.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.75% to 396,989 units (SEC Form 4)
- SEC Form 10-Q filed by Adaptive Biotechnologies Corporation
- Chief Commercial Officer, MRD Bobulsky Susan sold $31,176 worth of shares (1,299 units at $24.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.32% to 399,989 units (SEC Form 4)
- Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE